These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22958202)

  • 1. Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp.
    Sjöstrand M; Ericsson H; Hartford M; Norjavaara E; Eriksson JW
    Diabetes Obes Metab; 2013 Jan; 15(1):35-41. PubMed ID: 22958202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food.
    Ericsson H; Sjöberg F; Heijer M; Dorani H; Johansson P; Wollbratt M; Norjavaara E
    Diabetes Res Clin Pract; 2012 Dec; 98(3):436-44. PubMed ID: 23010558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.
    Norjavaara E; Ericsson H; Sjöberg F; Leonsson-Zachrisson M; Sjöstrand M; Morrow LA; Hompesch M
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3319-25. PubMed ID: 22723318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
    Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
    Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes.
    Korsatko S; Glettler K; Olsen KJ; Wutte A; Bock G; Koehler G; Mader JK; Semlitsch B; Pieber TR
    Diabetes Obes Metab; 2013 Mar; 15(3):241-5. PubMed ID: 23013357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
    Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
    Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body mass index and the efficacy of needle-free jet injection for the administration of rapid-acting insulin analogs, a post hoc analysis.
    de Galan BE; Engwerda EE; Abbink EJ; Tack CJ
    Diabetes Obes Metab; 2013 Jan; 15(1):84-6. PubMed ID: 22830987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
    Heise T; Nosek L; Klein O; Coester H; Svendsen AL; Haahr H
    Diabetes Obes Metab; 2015 Jul; 17(7):659-64. PubMed ID: 25772444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
    Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers.
    Li J; Wang Y; Han L; Sun X; Yu H; Yu Y
    Clin Ther; 2012 Dec; 34(12):2333-8. PubMed ID: 23195963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.
    Cernea S; Kidron M; Wohlgelernter J; Raz I
    Clin Ther; 2005 Oct; 27(10):1562-70. PubMed ID: 16330292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
    Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.
    Ericsson H; Röshammar D; Wollbratt M; Heijer M; Persson M; Ueda S; Leonsson-Zachrisson M; Norjavaara E
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):765-77. PubMed ID: 22943931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
    Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
    Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.
    Barrington P; Chien JY; Tibaldi F; Showalter HD; Schneck K; Ellis B
    Diabetes Obes Metab; 2011 May; 13(5):434-8. PubMed ID: 21251179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
    Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
    Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study.
    Xu H; Sheng L; Chen W; Yuan F; Yang M; Li H; Li X; Choi J; Zhao G; Hu T; Li Y; Zhang Y; Chen L
    Drug Des Devel Ther; 2016; 10():1619-26. PubMed ID: 27274195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.